All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
The European Commission approves daratumumab as front-line treatment in newly diagnosed multiple myeloma
Bookmark this article
The European Commission (EC) has approved a recent recommendation by the Committee for Medicinal Products for Human Use (CHMP) for use of daratumumab (Darzalex®) as first-line treatment for multiple myeloma (MM) patients (pts)1,2. Janssen’s daratumumab - in combination with bortezomib, melphalan, and prednisone (VMP) - has now gained approval by the EC for newly diagnosed (ND) MM pts who are ineligible for an autologous stem cell transplant (ASCT).
Authorization of daratumumab under this new indication is based on results from the ALCYONE study, a phase III, randomized, multi-center clinical trial with 706 participants, led by Dr Victoria Maria Mateos. The results of this study were published in the New England Journal of Medicine3 in February 2018 and presented at ASH 2017.
Daratumumab became available as front-line treatment in the US earlier this year, after approval by the Food and Drug Administration (FDA).
This approval provides NDMM pts in Europe, who are ineligible for an ASCT, with a new effective treatment combination.
- OncLive online. Daratumumab/VMP Combo Approved in EU for frontline Myeloma. https://www.onclive.com/web-exclusives/daratumumabvmp-combo-approved-in-eu-for-frontline-myeloma. [Assessed September 03 2018].
- PharmaTimes online. Janssen bags new EU approval for Darzalex. http://www.pharmatimes.com/news/janssen_bags_new_eu_approval_for_darzalex_1251100. [Assessed September 03 2018].
- Mateos M.V.et al. ALCYONE Trial Investigators. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. New England Journal of Medicine.2018 Feb 8; DOI:10.1056/NEJMoa1714678.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox